Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products
US6630126B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 12, 2001 |
| Grant date | Oct 7, 2003 |
| Priority date | — |
| Expiry date | Apr 19, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M5/1483
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of screening for pulmonary embolism uses gaseous phase polarized 129Xe which is injected directly into the vasculature of a subject. The gaseous 129Xe can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. Alternatively, the gas can be injected such that it remains as a gas in the bloodstream for a period of time (such as about 8-29 seconds). The injectable formulation of polarized 129Xe gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized 129Xe and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. One method injects the polarized 129Xe as a gas into a vein and also directs another quantity of polarized gas into the subject via inhalation. In this embodiment, the perfusion uptake allows arterial signal information and the injection (venous side) allows venous signal information. The dual delivery is used to generate a combined introduction path with a more complete image signal of both the arterial and venous side of the pulmonary vasculature. In this NMR imaging method, the p…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.